Wanbury has further strengthened its well-known brand - Coriminic, for children cold & sneezing usage, with launch of Coriminic CPM Drops (Chlorpheniramine Maleate) without combination of decongestant for pediatric/ children usage, to address the drug control notification restricting fixed-dose cold combinations in children under 4 years of age.

Alongside Corirninic CPM Drops, Wanbury is strengthening the Corirninic brand with Coriminic NS (Normal Saline) Nasal Drops, a non-systemic nasal decongestant solution designed to provide localised relief for children from nasal congestion, helping physicians navigate treatment options within government regulatory boundaries.

This launch comes in the context of recent advisories and regulatory restrictions issued by the Drugs Controller General of India (DCGI), which have limited the use of fixed-dose combinations, those containing Chlorpheniramine + Phenylephrine, in children below 4 years due to safety concerns.

This strategic move positions Wanbury to capture a significant share of the Rs 861 crore Cold Preparation Liquid market and navigate the restrictions laid by DCGI. With this expansion, Wanbury is poised to further consolidate its presence in the fast-growing children Cold Preparation Liquid market.  

Wanbury, one of India’s fastest growing pharmaceutical companies amongst the ‘Top 50 Companies’ in India (as per ORG-IMS), has a strong presence in API global market and domestic branded Formulation.